口腔鳞状细胞癌免疫检查点的研究进展

Co-inhibitory Immune Checkpoints in Oral Squamous Cell Carcinoma

以程序性细胞死亡1(programmed cell death 1,PD-1)免疫检查点阻断为代表的新型肿瘤免疫治疗,在临床上已经取得了突破性进展。然而,仍然有很多肿瘤患者对免疫检查点的治疗不响应。因此,进一步探讨免疫检查点的作用机制有助于口腔鳞状细胞癌的治疗。本文综述了部分共抑制免疫检查点信号的表达及其机制,并讨论将其作为口腔鳞状细胞癌的免疫治疗靶点的可能。

Clinical breakthroughs have been made in the treatment of cancer by immune checkpoint,especially by the antibody of PD-1.However,there are still many cancer patients who are not responsive to immune checkpoint blockade.Therefore,it is necessary to further study the mechanism of immune checkpoint,which could be exploited for oral squamous cell carcinoma(OSCC).In this review,we summarize the expression and the mechanism of partial co-inhibitory immune checkpoint molecules and discuss the possibility of targeting co-inhibitory immune checkpoints for the treatment of OSCC.